Supplier News Breaks Archives
Surescripts appoints new chief executive
August 20th, 2014
ARLINGTON, Va. – Tom Skelton has been named chief executive officer of national health information network Surescripts.
Skelton, who previously held leadership roles with Foundation Radiology Group, MED3000 and Misys Healthcare Systems. is slated to take the helm as CEO on Aug. 25, Surescripts said Wednesday.
He succeeds Harry Totonis, who stepped down as Surescripts president and CEO in March.
"The progress Surescripts has made in recent years is a clear indication of the strength of its relationships with pharmacies, providers, payers, pharmacy benefit managers, retail clinics, health information exchanges and many others," Skelton said in a statement. "Surescripts is well-positioned for continued success as we work collaboratively with our customers to navigate the complex and evolving landscape of American health care."
Currently, Surescripts connects 70% of doctors and 95% of community pharmacies for electronic prescribing.
"Surescripts is at a critical point in its growth, so Tom will play a key role as we continue to perfect e-prescribing and expand our clinical network to create a comprehensive, unified health care system that improves care outcomes, increases efficiency and decreases costs," stated Douglas Hoey, co-chairman of Surescripts and CEO of the National Community Pharmacists Association.
In addition to its e-prescribing capabilities, Surescripts connects more than 700 electronic health records applications and enables interoperable health information exchange among more than 100 health systems, representing 862 hospitals nationwide. Each year, more than 6 billion secure health information transactions cross the Surescripts network.
"Tom has a deep understanding of the provider workflow, having previously led firms which develop technology products for physicians and clinicians, and brings tremendous operational and management experience, as well as a proven ability to set a clear vision for the development and commercialization of new technologies," stated Surescripts co-chairman Steven Miller, M.D.